Connect with us

Press Release

CMS(867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity

Published

2 months ago

on

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals.

About CMS-D008

CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases.

Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity

Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles.

CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution

CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options.

The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference:

  1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564.
  2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23
  3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z
  4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7.

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Trakx expands Canton presence as CTIs become available through Five North’s Loop wallet

Published

1 day ago

on

April 18, 2026

By

Trakx, the leading platform for crypto-index trading, announced that its Crypto Tradable Indices (CTIs) are now available through Five North’s Loop wallet on Canton, enabling CTIs to be held and transferred on-chain through a Canton-native wallet environment. The milestone marks a new step in the evolution of Trakx’s index products beyond the Trakx platform and into the broader infrastructure of the Canton ecosystem.

With this integration, Trakx Crypto Tradable Indices gain a new layer of accessibility and portability on-chain. By becoming available through Loop, Five North’s wallet product for Canton, CTIs can now be held and transferred across the Canton Network, an institutional-grade blockchain environment designed for privacy and interoperability.

The development is strategically significant for Trakx as it continues to strengthen the infrastructure and distribution layer surrounding its crypto index products. While CTIs have historically been accessed primarily through the Trakx platform, their availability through Loop reflects a broader shift toward interoperability, partner integration, and professional distribution models across digital assets.

“This milestone is about more than wallet availability,” said Lionel Rebibo, CEO at Trakx. “It reflects the direction we believe digital asset products need to take: beyond standalone platform access and toward deeper integration within institutional-grade blockchain infrastructure. By making CTIs available through Loop on Canton, we are taking a concrete step toward broader B2B and B2B2C distribution, stronger interoperability, and a more scalable framework for partners looking to integrate structured digital asset exposure into their own environments.”

Canton Network plays an important role in that strategy. Designed as a privacy-enabled blockchain network with a strong institutional orientation, Canton provides the type of infrastructure environment that can support on-chain issuance, asset portability, and interoperable financial workflows. For Trakx, this creates a foundation for CTIs to evolve from platform-native products into assets that can be integrated into broader access and distribution models.

Five North‘s role in the Canton ecosystem gives additional strategic relevance to the launch. As a builder and operator of core infrastructure on Canton Network, including wallets, explorers, and validator systems, Five North occupies a meaningful position within the network. Its Loop wallet provides the practical layer through which CTIs can now be held and transferred on-chain, helping translate tokenization into real ecosystem usability.

For Trakx, the move is especially relevant in the context of partner-led adoption. The company sees increasing value in enabling B2B platforms, B2B2C distributors and other professional intermediaries to access more structured and infrastructure-ready models for digital asset exposure. In that sense, the integration is not simply a technical enhancement, but part of a broader distribution strategy focused on making CTIs easier to integrate, distribute, and use across professional environments.

As digital asset markets mature, infrastructure, accessibility, and interoperability are becoming just as important as product design. With CTIs now available through Five North’s Loop wallet on Canton, Trakx is advancing its objective of building not only better crypto index products, but also better infrastructure pathways for those products to be held, transferred and integrated across the next generation of on-chain finance.

About Trakx

Trakx is a crypto index investing platform offering Crypto Tradable Indices designed to provide structured exposure to digital asset markets. Its mission is to make crypto investing simpler, more transparent, and more accessible through index-based products built for both individual and professional use.

Contact Information

Gary Rebibo | CMO at Trakx | gary@trakx.io

Website | LinkedIn | X/Twitter | Discord | Telegram

Media Contact

Organization: Trakx

Contact Person: Gary Rebibo

Website: https://trakx.io/

Email: Send Email

City: Paris

State: France

Country:France

Release id:44145

The post Trakx expands Canton presence as CTIs become available through Five North’s Loop wallet appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

General Compute Launches ASIC-First Inference Cloud for Autonomous AI Agents

Published

1 day ago

on

April 18, 2026

By

General Compute today announced its inference cloud platform built for AI agents, working with early partners now ahead of general availability on May 15, 2026. The platform runs on purpose-built AI accelerators rather than general-purpose GPUs. More information is available at generalcompute.com.

SAN FRANCISCO — April 18, 2026 — General Compute Inc. today announced its inference cloud platform, which is designed for AI agent workloads. The company is working with early partners now, with general availability scheduled for May 15, 2026.

The platform runs on purpose-built AI accelerators rather than general-purpose graphics processors. Its architecture separates the prefill and decode stages of inference processing, allowing each stage to be scaled independently based on workload.

The platform is built to serve AI agents that make high volumes of LLM inference and tool calls, including AI agents that provision their own compute programmatically.

“The last 20 years we built for developers, the next 20 we will build for agents. On General Compute, AI agents can sign up on their own and provision their own inference. Our docs and API are optimized for both human and AI agent consumption,” said Jason Goodison, co-founder and Chief Technology Officer of General Compute.

Platform Overview

The platform offers an industry-standard API, allowing developers to integrate it into existing applications with minimal code changes. AI agents and developers alike can sign up, provision API keys, and begin making inference calls programmatically.

At launch, the platform will offer access to a range of open-source LLMs across multiple model families and parameter sizes. Customers can also deploy their own models on the company’s infrastructure.

Infrastructure

General Compute’s data center infrastructure operates on hydroelectric power. The company states that its accelerator hardware is air-cooled, and that its racks operate at lower power densities than comparable installations built on general-purpose processors.

The company publishes technical performance data for its platform on its website.

Availability

General Compute is working with early partners now, with general availability beginning May 15, 2026. Enterprise inquiries regarding dedicated infrastructure, service level agreements, and capacity planning may be directed to jason@generalcompute.com

About General Compute

General Compute Inc. is an inference cloud company headquartered in California. The company was founded by Jason Goodison and Finn Puklowski.

Contact

Jason Goodison, Co-founder and Chief Technology Officer General Compute Inc. jason@generalcompute.com generalcompute.com

Media Contact

Organization: General Compute Inc

Contact Person: Jason Goodison

Website: https://generalcompute.com

Email:
jason@generalcompute.com

Contact Number: +14257537667

Address:440 North Barranca Avenue

Address 2: 3780

City: Covina

State: California

Country:United States

Release id:44077

The post General Compute Launches ASIC-First Inference Cloud for Autonomous AI Agents appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Tempo Mails Launches Temporary Email Address Platform for Instant Disposable Inbox Access

Published

2 days ago

on

April 18, 2026

By

MIAMI, Florida, United States — April 18, 2026 — Tempo Mails today announced the launch of its free temporary email address platform, designed to help users create disposable email addresses instantly for sign-ups, verification codes, online trials, and privacy-focused browsing. The web-based service provides a temporary mailbox without registration and supports real-time inbox access for users who need a burner email without linking it to a personal account.

Available at tempomails.com, the platform is built for users who want a faster way to manage one-time online interactions while keeping their primary inbox separate from promotional messages, verification traffic, and unwanted follow-up emails. According to the company’s website, the service creates a temporary email address on page load, supports inbox history controls, and allows users to refresh, delete, or add new addresses from the interface. 

Tempo Mails said the service is intended for common online use cases such as account verification, e-commerce sign-ups, app testing, temporary registrations, and limited anonymous communication. The platform also supports temporary email send and receive workflows where users need short-term inbox access to receive OTPs, confirmation links, and service-related messages without using a permanent account. The site states that no sign-up is required and that inboxes are auto-cleared after use. 

The service includes features such as custom email alias options, real-time inbox refresh, auto-delete functionality, and multi-domain address generation. Tempo Mails also states that the platform is free to use and designed to work worldwide, giving users access to a disposable inbox through a browser-based interface rather than a downloadable application. 

“With Tempo Mails, the goal is to make privacy-focused email access simple for everyday users,” said James at Tempo Mails. “People often need a temporary mailbox for a single task, such as receiving a code or completing a registration, without exposing their personal inbox to long-term marketing traffic.”

The launch comes as more users look for practical ways to separate account creation and one-time online activity from their primary email accounts. By offering disposable email addresses that can be created in seconds, Tempo Mails is positioning the platform as a lightweight privacy tool for consumers, testers, developers, and online shoppers who need a burner email for short-term use.

About Tempo Mails
Tempo Mails is a web-based temporary email service that provides free temporary email address generation for users who want short-term inbox access without registration. The platform offers disposable email addresses, real-time inbox refresh, custom alias controls, and temporary mailbox features designed for account verification, online trials, and privacy-focused browsing. The service is available through tempomails.com and is designed for fast access across devices.

Media Contact

Organization: Tempo Mails

Contact Person: James

Website: https://tempomails.com/

Email:
contact@tempomails.com

Country:United States

Release id:44144

The post Tempo Mails Launches Temporary Email Address Platform for Instant Disposable Inbox Access appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us